Tecsys (TCS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Mar, 2026Executive summary
Achieved record Q3 2026 SaaS revenue of $20.1M, up 17% year-over-year, and record adjusted EBITDA, up 43%, driven by strong bookings in healthcare and distribution verticals, with no migration bookings included.
Net profit for Q3 2026 was $1.7M, up 45% year-over-year, with EPS rising to $0.12 from $0.08.
Commercial launch of TecsysIQ, an AI intelligence layer, to enhance data unification and actionable insights for healthcare customers.
Pipeline at quarter-end increased 30% year-over-year, reflecting robust demand and market momentum.
Implemented a 7% workforce reduction post-quarter, expected to yield $8.1M in annual cost savings, with a $4.5M restructuring charge in Q4.
Financial highlights
SaaS ARR reached $83.3M, up 10% (16% constant currency) year-over-year; Elite SaaS ARR grew 17% (23% constant currency).
Q3 2026 total revenue was $48.5M; gross margin improved to 51% from 47% year-over-year.
Adjusted EBITDA for Q3 was $5M, up from $3.5M; margin improved to 10.4%.
Year-to-date (nine months) SaaS revenue was $58.9M, up 21%; total revenue for the period was $143.1M, up 10%.
SaaS RPO was $248.9M, up 18% (24% constant currency) year-over-year.
Outlook and guidance
Full-year FY26 guidance reaffirmed: SaaS revenue growth of 20%-22%, total revenue growth of 8%-10%, and adjusted EBITDA margin of 8%-9%.
Q4 professional services revenue expected to be similar to Q3, reflecting backlog trends.
Projected SaaS margin expansion, with Elite SaaS product margins running over 75% on latest infrastructure.
Adjusted EBITDA margin guidance for FY26 at mid-point, with directional targets for FY27 and FY28.
Quarterly dividend of $0.09/share declared, payable April 15, 2026.
Latest events from Tecsys
- Record SaaS-driven revenue, margin expansion, and raised FY25 revenue outlook.TCS
Q3 20258 Jul 2026 - SaaS revenue up 25%, total revenue $46M, and adjusted EBITDA up 24% with strong healthcare growth.TCS
Q1 20262 Jul 2026 - Record SaaS-driven revenue, margin expansion, and strong FY27 growth outlook.TCS
Q4 202630 Jun 2026 - SaaS-driven growth and innovation position the company to capture a $3B ARR supply chain market.TCS
Investor presentation30 Jun 2026 - SaaS-driven growth, strategic focus, and all proposals approved with no shareholder questions.TCS
AGM 202515 May 2026 - Directors and auditors re-elected, SaaS revenue surged, and strategic healthcare focus reaffirmed.TCS
AGM 202415 May 2026 - SaaS revenue rose 33%, bookings 57%, and guidance was reaffirmed amid strong governance actions.TCS
Q1 202522 Apr 2026 - SaaS revenue up 29% year-over-year, fueling record profit and strong healthcare momentum.TCS
Q4 202522 Apr 2026 - Record SaaS growth and margin gains drive strong FY2024 results and positive outlook.TCS
Q4 20243 Feb 2026